Phase II and Phase III data from selected molecules to treat moderate to severe plaque psoriasis show that the 210 mg dose of brodalumab from Amgen Inc. (NASDAQ:AMGN) has the highest placebo-adjusted PASI 75 response rate at 82%. Among the three compounds in the clinic, Phase II data for brodalumab showed a slightly higher rate of adverse events than placebo, while Phase II data for ixekizumab from Eli Lilly and Co. (NYSE:LLY) and for secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN) showed similar AE rates between the treatment and placebo arms. No SAEs